Macrophage Immunometabolism in Epicardial Adipose Tissue and Obesity-Related Atrial Fibrillation
Abstract
Obesity is a crucial risk factor for atrial fibrillation (AF). The underlying mechanism is partly related to increased epicardial adipose tissue (EAT). EAT directly contacts the adjacent cardiac myocardium where immune and metabolic activities interact. Obesity induces inflammatory and metabolic signals within EAT, which directly influence atrial structure and electrical remodeling. However, the specific immunometabolic mechanisms linking EAT macrophages to atrial arrhythmogenesis remain unclear. We highlight evidence that nutrient excess, hypoxia, oxidative stress, and adipocyte-derived inflammatory signals reprogram glucose, lipid, and amino acid metabolism in EAT macrophages, promoting persistent pro-inflammatory and profibrotic states. Metabolic pathways involving mechanistic target of rapamycin (mTOR)-hypoxia-inducible factor-1α (HIF-1α) signaling, fatty acid and ceramide metabolism, the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, and metabolic-epigenetic interactions may sustain macrophage activation and amplify local inflammation. These metabolically reprogrammed macrophages subsequently promote atrial fibrosis, electrical heterogeneity, and autonomic dysfunction, while systemic inflammation, insulin resistance, and neurohumoral activation further reinforce the EAT-atrial pathological circuit. Emerging evidence also suggests that EAT characteristics may improve AF risk stratification and that weight loss and metabolic interventions can…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.